CNB-001, a synthesized derivative of curcumin, activates CaMKII and enhances memory
| Project/Area Number |
24790540
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Musashino University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | クルクミン / 海馬 / 長期増強 / 記憶 / CaMKⅡ / CaMKII / アルツハイマー病 / 認知症 |
|---|
| Outline of Final Research Achievements |
We have recently demonstrated that oral administration of CNB-001, a synthesized pyrazole derivative of curcumin, enhances memory in a rat object recognition test. CNB-001 could be useful in the development of therapeutic drugs for senile dementia.
This study investigated mechanisms underlying the memory-enhancing effect of CNB-001, and found that CNB-001 promoted NMDA receptor- and CaMKII-dependent long-term potentiation (LTP) of rat hippocampal slices, not via the MAP kinase or PKC cascade.
|
Report
(4 results)
Research Products
(4 results)
